UP!

RNN $5.24

RNN target price
5.24
0
0

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2019 2019-05-06 0.00 0.00
Q4 2018 2019-03-08 -1.08 -1.08
Q3 2018 2018-11-02 -2.04 -2.04

Ratings

2016-03-27 Reiterated Rating FBR & Co. Buy $3.00
2016-02-29 Reiterated Rating Roth Capital Buy $1.75
2016-02-10 Reiterated Rating FBR & Co. Outperform $3.00
2015-11-03 Reiterated Rating Roth Capital Buy $3.00
2015-09-29 Reiterated Rating Roth Capital Buy $3.00
2015-08-14 Reiterated Rating MLV & Co. Buy $1.25
2015-08-11 Reiterated Rating Roth Capital Buy $3.00
2015-05-13 Reiterated Rating Roth Capital Buy $3.00
2015-03-20 Initiated Coverage MLV & Co. Buy $1.25
2014-09-16 Initiated Coverage Laidlaw Buy $3.50
2014-03-24 Initiated Coverage Brinson Patrick Outperform
2014-01-09 Initiated Coverage Roth Capital Buy $3.00
2011-06-16 Resumed Brean Murray Buy $3
2016-03-27 Reiterated Rating FBR & Co. Buy $3.00
2016-02-29 Reiterated Rating Roth Capital Buy $1.75
2016-02-10 Reiterated Rating FBR & Co. Outperform $3.00
2015-11-03 Reiterated Rating Roth Capital Buy $3.00
2015-09-29 Reiterated Rating Roth Capital Buy $3.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

Major Shareholders

Name Relationship Total Shares Holding stocks
Ahn Chang Ho 3.37%  (6010000) RNN /
Rexgene Biotech Co., Ltd. 3.09%  (5505956) RNN /
Park Young Soon 1.14%  (2040500) RNN /
Rhee Jang Han 1.12%  (2000000) RNN /
Jeong Tae Heum CFO and Secretary 0.28%  (505000) RNN /
Brandt Peter C. 0.08%  (150000) AUXL / RNN /
Kwon Suk Hyung 0.06%  (114255) RNN /
McIntosh David M 0.01%  (25990) RNN /
Suzdak Peter David Chief Executive Officer 0.01%  (22250) RNN /
Kang Y Michele 0.01%  (10000) RNN /
Beever Charles 0.01%  (10000) RNN /